News

 

 

September 1, 2022

Adecto Pharmaceuticals awarded Phase II NCI SBIR grant to continue development of an ADAM8 cancer diagnostic

 

 

August 11, 2020

Adecto Pharmaceuticals president Dr. Gail Sonenshein receives Tufts University School of Medicine 2020 Zucker Award for outstanding career achievements in women's health research

 

 

May 24, 2019

Adecto Pharmaceuticals awarded Phase I NCI SBIR grant for development of ADAM8 cancer diagnostic

 

 

October 22, 2018

Adecto Pharmaceuticals awarded multimillion-dollar NCI SBIR grant to continue development of ADAM8 targeted therapy

 

 

March 1, 2018

Adecto Pharmaceuticals selected to participate in MassBio’s MassCONNECT mentoring program

 

 

April 2, 2017

Adecto Pharmaceuticals presents poster on selection of lead candidate therapeutic antibodies at the 2017 AACR annual meeting

 

 

April 15, 2016

Adecto Pharmaceuticals awarded Phase I NCI STTR grant for the development of ADAM8 targeted therapies

 

 

April 13, 2015

Adecto Pharmaceuticals wins Tufts $100K New Ventures Competition

 

 

March 18, 2014

New Hope for Tough-to-Treat Breast Cancers

Tufts researchers find promising target in battle against aggressive tumors